Confidence in the ability diagnose allergy has been shown to increase when ImmunoCAP Whole Allergen test results are added to clinical history.1,2
ImmunoCAP Specific IgE has excellent clinical performance:3**
*In patients with symptoms of eczema, wheeze and/or asthma, and rhinitis in primary care.
**Depending on the allergen
We work hard to maintain the highest possible quality. Results should be accurate not only now, but also over time to enable clinicians to follow patient’s disease progression and adjust management when needed.
Our quality system and production process controls are designed to ensure allergen consistency, which enables ImmunoCAP tests to provide precise, reproducible, quantification of specific IgE antibodies, confirmed in multiple studies and quality schemes.4,5
ImmunoCAP values referenced in clinical diagnostic decision points cannot be applied to results from other diagnostic systems.8-11
Factors to consider for a final diagnosis
The diagnostic value of quantitative specific IgE levels is visualized in a generic risk curve. This curve is based on thousands of ImmunoCAP Specific IgE test results and demonstrates the relationship between increasing IgE levels and the increasing probability of symptomatic allergy. A general rule of thumb is that the higher the IgE antibody value, the greater the probability of symptoms appearing when exposed to the allergen.12-14